Published in Nat Genet on December 26, 2010
Five years of GWAS discovery. Am J Hum Genet (2012) 12.97
AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol (2012) 10.42
Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) (2012) 4.04
Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. Science (2014) 3.16
Stratifying type 2 diabetes cases by BMI identifies genetic risk variants in LAMA1 and enrichment for risk variants in lean compared to obese cases. PLoS Genet (2012) 2.34
Metformin: multi-faceted protection against cancer. Oncotarget (2011) 2.00
The ATM protein kinase and cellular redox signaling: beyond the DNA damage response. Trends Biochem Sci (2011) 1.91
A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts. Diabetologia (2012) 1.83
Molecular mechanism of action of metformin: old or new insights? Diabetologia (2013) 1.71
Signal transduction by mitochondrial oxidants. J Biol Chem (2011) 1.65
Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. Lancet Diabetes Endocrinol (2014) 1.64
Preserved DNA Damage Checkpoint Pathway Protects against Complications in Long-Standing Type 1 Diabetes. Cell Metab (2015) 1.54
Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nat Genet (2016) 1.48
Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes (2013) 1.44
Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications. Rev Diabet Stud (2012) 1.42
Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics (2012) 1.38
Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging (Albany NY) (2012) 1.31
Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. Diabetes (2014) 1.29
Gene-environment and gene-treatment interactions in type 2 diabetes: progress, pitfalls, and prospects. Diabetes Care (2013) 1.20
Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol (2013) 1.20
Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions. Blood (2013) 1.18
Metformin pharmacogenomics: current status and future directions. Diabetes (2014) 1.15
Type 2 Diabetes Genetics: Beyond GWAS. J Diabetes Metab (2012) 1.09
Pharmacogenomics in clinical practice and drug development. Nat Biotechnol (2012) 1.08
Gerosuppressant metformin: less is more. Aging (Albany NY) (2011) 1.08
A common 5'-UTR variant in MATE2-K is associated with poor response to metformin. Clin Pharmacol Ther (2011) 1.07
The role of ATM in response to metformin treatment and activation of AMPK. Nat Genet (2012) 1.06
The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program. Diabetes Care (2012) 1.06
Type 2 diabetes and obesity: genomics and the clinic. Hum Genet (2011) 1.04
Metformin in obesity, cancer and aging: addressing controversies. Aging (Albany NY) (2012) 1.04
The pharmacogenetics of type 2 diabetes: a systematic review. Diabetes Care (2014) 1.03
The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res (Phila) (2011) 1.02
Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. PLoS One (2012) 1.02
The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes (2013) 1.02
Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer. Aging (Albany NY) (2011) 1.01
PUMA: a unified framework for penalized multiple regression analysis of GWAS data. PLoS Comput Biol (2013) 1.00
A genome-wide association study suggests an association of Chr8p21.3 (GFRA2) with diabetic neuropathic pain. Eur J Pain (2015) 0.97
An update on the pharmacogenomics of metformin: progress, problems and potential. Pharmacogenomics (2014) 0.97
Genetic variants in PARP1 (rs3219090) and IRF4 (rs12203592) genes associated with melanoma susceptibility in a Spanish population. BMC Cancer (2013) 0.95
Genetics and genomics of radiotherapy toxicity: towards prediction. Genome Med (2011) 0.95
Ataxia-telangiectasia: future prospects. Appl Clin Genet (2014) 0.94
Genomics: Drugs, diabetes and cancer. Nature (2011) 0.94
Genetics of type 2 diabetes: insights into the pathogenesis and its clinical application. Biomed Res Int (2014) 0.92
Alterations in cellular energy metabolism associated with the antiproliferative effects of the ATM inhibitor KU-55933 and with metformin. PLoS One (2012) 0.92
Genome-Wide Association and Trans-ethnic Meta-Analysis for Advanced Diabetic Kidney Disease: Family Investigation of Nephropathy and Diabetes (FIND). PLoS Genet (2015) 0.92
Sequencing and analysis of a South Asian-Indian personal genome. BMC Genomics (2012) 0.91
A Genome-wide Association Study Provides Evidence of Sex-specific Involvement of Chr1p35.1 (ZSCAN20-TLR12P) and Chr8p23.1 (HMGB1P46) With Diabetic Neuropathic Pain. EBioMedicine (2015) 0.90
The role of ATM in response to metformin treatment and activation of AMPK. Nat Genet (2012) 0.90
ATM and LKB1 dependent activation of AMPK sensitizes cancer cells to etoposide-induced apoptosis. Cancer Lett (2012) 0.89
Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med (2012) 0.89
Pharmacogenetics and personalized treatment of type 2 diabetes. Biochem Med (Zagreb) (2013) 0.89
Pharmacogenomics discovery and implementation in genome-wide association studies era. Wiley Interdiscip Rev Syst Biol Med (2012) 0.88
Pharmacogenetics in type 2 diabetes: potential implications for clinical practice. Genome Med (2011) 0.87
Genetic epidemiology of type 2 diabetes and cardiovascular diseases in Africa. Prog Cardiovasc Dis (2013) 0.86
Pharmacogenetics of oral antidiabetic drugs. Int J Endocrinol (2013) 0.86
Genetics of Type 2 Diabetes and Clinical Utility. Genes (Basel) (2015) 0.86
Personalized medicine in Type 2 Diabetes. Biomedicine (Taipei) (2014) 0.85
World congress on insulin resistance, diabetes, and cardiovascular disease: Part 1. Diabetes Care (2011) 0.85
Introduction to personalized medicine in diabetes mellitus. Rambam Maimonides Med J (2014) 0.85
Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy. Oncotarget (2014) 0.84
Genetic determinants of cardiometabolic risk: a proposed model for phenotype association and interaction. J Clin Lipidol (2012) 0.84
Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther (2014) 0.83
Personalized medicine in diabetes mellitus: current opportunities and future prospects. Ann N Y Acad Sci (2015) 0.83
Variation in the ATM gene may alter glycemic response to metformin. Circ Cardiovasc Genet (2011) 0.82
Does metformin work for everyone? A genome-wide association study for metformin response. Curr Diab Rep (2011) 0.82
Type 2 diabetes: genetic data sharing to advance complex disease research. Nat Rev Genet (2016) 0.82
A pharmacogenetic association between a variation in calpain 10 (CAPN10) gene and the response to metformin treatment in patients with type 2 diabetes. Eur J Clin Pharmacol (2014) 0.81
The genetics of drug efficacy: opportunities and challenges. Nat Rev Genet (2016) 0.81
Recessive mutations in the cancer gene Ataxia Telangiectasia Mutated (ATM), at a locus previously associated with metformin response, cause dysglycaemia and insulin resistance. Diabet Med (2015) 0.81
Insulin signaling and insulin resistance. J Investig Med (2013) 0.80
Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents. Pharmgenomics Pers Med (2016) 0.79
Effect of zinc supplementation on insulin secretion: interaction between zinc and SLC30A8 genotype in Old Order Amish. Diabetologia (2014) 0.79
Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery. Nat Rev Endocrinol (2016) 0.79
Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer. Cell Cycle (2013) 0.79
Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients. Clin Exp Med (2014) 0.79
Genomic Characterization of Metformin Hepatic Response. PLoS Genet (2016) 0.79
Metformin pharmacogenomics: biomarkers to mechanisms. Diabetes (2014) 0.78
Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary Tumorigenesis. Curr Pharmacol Rep (2015) 0.78
Genetic variants predicting left ventricular hypertrophy in a diabetic population: a Go-DARTS study including meta-analysis. Cardiovasc Diabetol (2013) 0.78
Genomic technology applied to pharmacological traits. JAMA (2011) 0.78
Personalized medicine in diabetes: the role of 'omics' and biomarkers. Diabet Med (2016) 0.78
10 Years of GWAS Discovery: Biology, Function, and Translation. Am J Hum Genet (2017) 0.78
The pharmacogenetics of metformin. Diabetologia (2017) 0.77
Genetic predisposition to type 2 diabetes is associated with impaired insulin secretion but does not modify insulin resistance or secretion in response to an intervention to lower dietary saturated fat. Genes Nutr (2012) 0.77
Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies? PPAR Res (2015) 0.77
The role of ATM in response to metformin treatment and activation of AMPK. Nat Genet (2012) 0.77
Allele and genotype frequency of a genetic variant in ataxia telangiectasia mutated gene affecting glycemic response to metformin in South Indian population. Indian J Endocrinol Metab (2014) 0.77
The role of genetic factors and kidney and liver function in glycemic control in type 2 diabetes patients on long-term metformin and sulphonylurea cotreatment. Biomed Res Int (2014) 0.77
Leveraging Genetics to Advance Type 2 Diabetes Prevention. PLoS Med (2016) 0.76
LDGIdb: a database of gene interactions inferred from long-range strong linkage disequilibrium between pairs of SNPs. BMC Res Notes (2012) 0.75
Highlights from the latest pharmacogenomic genome-wide association studies. Pharmacogenomics (2013) 0.75
The role of the p53 tumor suppressor in metabolism and diabetes. J Endocrinol (2016) 0.75
Final "perspectives on the news": American Association of Clinical Endocrinology and American Diabetes Association 2011. Diabetes Care (2011) 0.75
The cell-autonomous mechanisms underlying the activity of metformin as an anticancer drug. Br J Cancer (2016) 0.75
Patient profiling in diabetes and role of canagliflozin. Pharmgenomics Pers Med (2014) 0.75
The Application of Genomics in Diabetes: Barriers to Discovery and Implementation. Diabetes Care (2016) 0.75
Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs. Pharmacogenomics J (2016) 0.75
Impact of ATM and SLC22A1 Polymorphisms on Therapeutic Response to Metformin in Iranian Diabetic Patients. Int J Mol Cell Med (2016) 0.75
Endocrine abnormalities in ataxia telangiectasia: findings from a national cohort. Pediatr Res (2016) 0.75
PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet (2007) 209.92
A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet (2007) 52.68
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 34.34
Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science (2007) 32.97
A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet (2009) 30.09
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
GenABEL: an R library for genome-wide association analysis. Bioinformatics (2007) 18.10
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res (2004) 9.70
Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J (2000) 7.77
Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol (2008) 6.62
Identification and functional analysis of human transcriptional promoters. Genome Res (2003) 6.23
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care (2009) 6.17
Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet (2009) 4.61
Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J (2008) 4.51
Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab (2010) 4.14
Similar substrate recognition motifs for mammalian AMP-activated protein kinase, higher plant HMG-CoA reductase kinase-A, yeast SNF1, and mammalian calmodulin-dependent protein kinase I. FEBS Lett (1995) 3.42
ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab (2006) 3.38
Analysis of the role of the AMP-activated protein kinase in the response to cellular stress. Methods Mol Biol (2000) 2.08
Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis. J Clin Invest (2007) 2.03
Etoposide induces ATM-dependent mitochondrial biogenesis through AMPK activation. PLoS One (2008) 1.94
Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. Int J Radiat Oncol Biol Phys (2010) 1.89
AICAR induces phosphorylation of AMPK in an ATM-dependent, LKB1-independent manner. Mol Cell Biochem (2007) 1.65
An unusual form of diabetes mellitus in ataxia telangiectasia. N Engl J Med (1970) 1.38
Extreme insulin resistance in ataxia telangiectasia: defect in affinity of insulin receptors. N Engl J Med (1978) 1.37
Impaired insulin secretion in a mouse model of ataxia telangiectasia. Am J Physiol Endocrinol Metab (2007) 1.34
The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes. Diabet Med (2006) 1.26
Ataxia-telangiectasia: an overview. Kroc Found Ser (1985) 1.15
Ataxia telangiectasia mutated and p21CIP1 modulate cell survival of drug-induced senescent tumor cells: implications for chemotherapy. Clin Cancer Res (2008) 1.14
ATM is upregulated during the mitogenic response in peripheral blood mononuclear cells. Blood (1999) 1.13
Ataxia-telangiectasia: structural diversity of untranslated sequences suggests complex post-transcriptional regulation of ATM gene expression. Nucleic Acids Res (1997) 1.04
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Finding the missing heritability of complex diseases. Nature (2009) 67.95
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet (2007) 52.68
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet (2008) 43.63
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science (2007) 37.88
Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet (2008) 35.06
Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science (2007) 32.97
Integrating common and rare genetic variation in diverse human populations. Nature (2010) 32.30
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet (2009) 30.09
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
A fine-scale map of recombination rates and hotspots across the human genome. Science (2005) 26.82
A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet (2003) 26.59
Population genomics of human gene expression. Nat Genet (2007) 24.49
Genomewide association analysis of coronary artery disease. N Engl J Med (2007) 24.38
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet (2008) 22.35
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet (2008) 20.73
Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet (2008) 20.66
Large recurrent microdeletions associated with schizophrenia. Nature (2008) 20.25
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
Genome-wide associations of gene expression variation in humans. PLoS Genet (2005) 17.27
The fine-scale structure of recombination rate variation in the human genome. Science (2004) 17.05
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet (2010) 16.96
Genome-wide association analysis identifies 20 loci that influence adult height. Nat Genet (2008) 16.92